No abstract

No abstract

Objective: Coronavirus disease 2019 (COVID-19) is a current new virulent disease rising its transmission and fatality with each passing day in the worldwide population. COVID-19 is emerged as a respiratory infection and a suspicious origin of animals and transmission to human in Wuhan, China on December 2019. Later this, the virus was transmitted from person to person through droplets and contacts. The World Health Organization, Centers for Disease Control and Prevention, and the National Health Commission of the People’s Republic of China have taken immediate action to reduce transmission and fatality associated with COVID-19 as minimum as possible. However, action has failed to stop transmission of COVID-19 from China to other countries. Since there was no chain break of the virus, the chances are more to increase the case number and fatality. Hence, the study has been designed to perceive the current effect of COVID-19 on the global population and its fatality. The study also focused on review related to treatment for COVID-19. Material and Methods: Online database of epidemic disease COVID-19 cases number was collected from www.channelnewsasia.com on 7th April 2020. This data was used to observe the past and present circumstances in the global population and its fatality. The effect of treatment on COVID-19 was reviewed from the few databases of clinical trials (antiviral and antibacterial drugs). Results: The online data are used to observe a significant increase ratio of COVID-19 cases and its fatality rate in worldwide as well as country wise. The COVID-19 cases are high in the United States (27.5%), whereas the fatality rate is high in Italy (12.47%). The prevalence of COVID-19 is expected to be reaching 4 million by the end of April 2020 and the fatality rate also might be reached high. Conclusion: We have come to the conclusion that the effect of COVID-19 on the global population is significantly increased and the fatality rate also elevated (2.48% to 5.52%). The hydroxychloroquine-azithromycin combination treatment has shown significant improvement in patients with COVID-19 compared to treat with other drugs.

Background: Cardiovascular disease (CVD) is a major cause of death in diabetic subjects. Glycaemic status is one of the vital factor involved in vascular complications. It was clear the effect of glycaemia on microvascular complications, but uncertain on macrovascular complications. As we know oxidative stress plays a major role in the development of atherosclerosis and cardiovascular disease. Since oxidative stress is a risk factor for cardiovascular disease, the study has designed to perceive an association between HbA1c and oxidative stress in patients with type 2 diabetes mellitus for early prediction of cardiovascular events.Methods: 120 subjects were taken into the study, among these 60 type 2 diabetic subjects and remaining 60 subjects were healthy controls. The parameters like HbA1c, MDA and FRAP were estimated by established methods. ‘Kruskal Wallis’ test was used for variables in the parameters and Pearson correlation test was used to perform correlation between HbA1c and oxidative stress.Results: High level of HbA1c and MDA, low level of FRAP were found in patients with type 2 diabetes than healthy controls. The study was also found HbA1c have positive association with malondialdehyde (MDA) and negative association with FRAP.Conclusions: HbA1c was positively associated with oxidative stress in patients with type 2 diabetes mellitus. In this scenario, type 2 diabetic patients with high level of HbA1c might have risk of cardiovascular events.